#United States #Atlanta #Lipocine #Epilepsy Treatment #LPCN 2101

Lipocine's Key Presentation at AES 2025: LPCN 2101 Insights

Lipocine Inc., a biopharmaceutical company known for its innovative oral delivery technology, has announced that two vital abstracts concerning its LPCN 2101 candidate have been accepted for presentation at the upcoming 2025 American Epilepsy Society (AES) annual meeting. This meeting will take place from December 5 to 9 in Atlanta, Georgia, an important gathering for professionals in the epilepsy and seizure disorder fields.

About LPCN 2101

LPCN 2101 represents Lipocine’s commitment to addressing significant unmet needs in epilepsy treatment. This investigational product is aimed at improving the treatment landscape for individuals with epilepsy, particularly focusing on women who may experience different challenges compared to their male counterparts.

The first abstract set for presentation is titled "Oral Toxicokinetics of a Bioidentical GABAA Receptor Modulating Neuroactive Steroid (NAS) Anti-seizure Medication (ASM) Candidate for Women with Epilepsy (WWE)", authored by a team led by Joshua C. Weavil. This research will delve into the pharmacokinetic profile of this new ASM, highlighting its potential efficacy and safety for female patients.

Scheduled for presentation on December 7, 2025 from noon to 2 PM, this session will be crucial for clinicians who care for women with epilepsy and are looking for tailored therapeutic options that consider gender-based differences in treatment responses.

The second abstract, titled "Clinical Pharmacokinetics (PK) and Tolerability of a Novel Oral GABAA Receptor Positive Allosteric Modulating (PAM) Candidate for Epilepsy," will be showcased by authors including Min-Jee Goh and Jonathan Ogle. This presentation will occur on December 8, 2025 from noon to 1:45 PM, providing insights into how this PAM candidate could reshape the treatment paradigm for epilepsy.

With Abstract Numbers 2.331 and 3.354 respectively, both presentations aim to offer a deeper understanding of the pharmacological properties and patient tolerability related to these innovative epilepsy therapies.

The Importance of the AES Annual Meeting

The AES annual meeting is a major event that brings together professionals from various backgrounds in the epilepsy community, including researchers, clinicians, and industry leaders. The acceptance of Lipocine's abstracts at this high-profile conference serves as a validation of the company's research efforts and opens the door for engaging discussions about the future of epilepsy treatment.

Lipocine's association with AES 2025 showcases its dedication to advancing science and providing therapeutic alternatives that can improve the lives of those affected by epilepsy. The company believes that their oral delivery technology provides an advantage over existing treatment options, which may involve different modalities. Effective oral delivery mechanisms can enhance patient compliance and optimize therapeutic outcomes.

Lipocine's Broader Aspirations

Known for its innovative drug development pipeline, Lipocine has multiple candidates in various stages of clinical development. Besides LPCN 2101, their portfolio includes treatments for postpartum depression, essential tremor, and liver cirrhosis, among others. These candidates are designed to deliver patient-friendly oral options, targeting large markets with significant medical needs.

Moreover, Lipocine has been actively pursuing partnership opportunities to amplify their research efforts and accelerate the development timelines for these crucial therapies.

To learn more about Lipocine’s initiatives and products, visit www.lipocine.com.

Conclusion

The presentation of LPCN 2101 abstracts at the AES 2025 meeting marks a significant step for Lipocine. It not only reinforces their commitment to innovative solutions in healthcare but also highlights the ongoing need for more effective treatments for epilepsy, especially in populations that have been historically underserved. As the event approaches, anticipation builds for what could potentially be breakthrough information for managing epilepsy more effectively.

Lipocine continues to pave the way forward in biopharmaceutical advancements, and the AES conference offers a platform for groundbreaking dialogue and future collaborations that can drive significant changes in epilepsy care.